-
1 Comment
Shanghai Henlius Biotech, Inc is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 71.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 32.2.
Shanghai Henlius Biotech, Inc's total revenue rose by 424.8% to $477M since the same quarter in the previous year.
Its net income has increased by 37.7% to $-546M since the same quarter in the previous year.
Finally, its free cash flow grew by 62.5% to $-232M since the same quarter in the previous year.
Based on the above factors, Shanghai Henlius Biotech, Inc gets an overall score of 4/5.
| ISIN | CNE100003N76 |
|---|---|
| Exchange | HK |
| Sector | Healthcare |
| Industry | Biotechnology |
| CurrencyCode | HKD |
| Market Cap | 20B |
|---|---|
| PE Ratio | 23.65 |
| Target Price | 34.6856 |
| Beta | 0.83 |
| Dividend Yield | None |
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops : HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma and limited-stage small cell lung cancer. HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2696.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
